Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia

Leukemia

Volumn 22, Issue 6, 2008, Pages 1125-1130

  Habib, A ^a   Hamade, E ^a   Mahfouz, R ^a   Nasrallah, M S ^a   de The H ^b   Bazarbachi, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCOPROTEIN P 15095; INDOMETACIN; NITROBLUE TETRAZOLIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOIC ACID;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

EID: 45149106303     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.59     Document Type: Article

References (36)

1. Sanz MA, Fenaux P, Lo Coco F, European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231-1235.
2. De The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
3. Warrell Jr RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189.
4. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
5. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
6. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
7. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
9. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R et al. Combined treatment with arsenic trioxide and all-transretinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334.
10. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-10452.
11. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-3473.
12. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006; 107: 2627-2632.
13. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134.
14. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2 705-713.
15. Zhu J, Koken M, Guignon F, Chelbi-Alix MK, Degos L, Yi Wang Z et al Arsenic-induced PML targeting onto nuclear bodies implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978-3983.
16. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191.
17. Rocca B, Spain LM, Ciabattoni G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J Immunol 1999; 162: 4589-4597.
18. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999; 103: 1469-1477.
19. Rocca B, Morosetti R, Habib A, Maggiano N, Zassadowski F, Ciabattoni G et al. Cyclooxygenase-1, but not 2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation. Leukemia 2004; 18: 1373-1379.
20. Jiang YJ, Xu TR, Lu B, Mymin D, Kroeger EA, Dembinski T et al. Cyclooxygenase expression is elevated in retinoic acid-differentiated U937 cells. Biochim Biophys Acta 2003; 1633: 51-60.
21. Schneider N, Lanz S, Ramer R, Schaefer D, Goppelt-Struebe M. Up-regulation of cyclooxygenase-1 in neuroblastoma cell lines by retinoic acid and corticosteroids. J Neurochem 2001; 77: 416-424.
22. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994; 91 5252-5256.
23. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268: 23448-23454.
24. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77 1080-1086.
25. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner P et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: Isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281-1287.
26. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: An alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-1173.
27. Khanna-Gupta A, Zibello T, Simkevich C, Rosmarin AG, Berliner N. Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation. Blood 2000; 95: 3734-3741.
28. Murate T, Suzuki M, Hattori M, Takagi A, Kojima T, Tanizawa T et al Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J Biol Chem 2002; 277: 9936-9943.
29. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S. Physical interaction between retinoic acid receptor and Sp1: Mechanism for induction of urokinase by retinoic acid. Blood 1999; 93: 4264-4276.
30. Xu XM, Tang JL, Chen X, Wang LH, Wu KK. Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J Biol Chem 1997; 272: 6943-6950.
31. Ulich TR, Dakay EB, Williams JH, Ni RX. In vivo induction of neutrophilia, lymphopenia, and diminution of neutrophil adhesion by stable analogs of prostaglandins E1, E2, and F2 alpha. Am J Pathol 1986; 124: 53-58.
32. Berk LB, Patrene KD, Boggs SS. 16, 16-Dimethyl prostaglandin E2 and/or syngeneic bone marrow transplantation increase mouse survival after supra-lethal total body irradiation. Int J Radiat Oncol Biol Phys 1990; 18: 1387-1392.
33. Hanson WR, Ainsworth EJ. 16, 16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res 1985; 103: 196-203.
34. Benoit G, Roussel M, Pendino, F, Ségal-Bendirdjian E, Lanotte M. Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: Another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene 2001; 20 7161-7177.
35. Guillemin MC, Raffoux E, Vitoux D. Kogan S, Soilihi H, Lallemand-Breitenbach V et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 2002; 196: 1373-1380.
36. Kamashev D, Vitoux D, De Thé H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004; 199: 1163-1174.